MONITORING THERAPYLaboratory monito

MONITORING THERAPY
Laboratory monitoring should include a complete
blood count performed monthly for 3 months to evaluate
for the presence of hemolytic (or, less commonly,
aplastic) anemia. Thereafter, quarterly to semiannual
complete blood counts should be obtained. A comprehensive
metabolic panel should be checked monthly
for 3 months, then every 4–6 months thereafter, paying
special attention to the liver enzymes, particularly in
those patients who are taking hepatotoxic medications
and in those patients with porphyria. Quarterly to
semiannual chemistries should be followed while on
maintenance therapy.
Proposed guidelines for monitoring for the development
of ocular toxicity vary widely in the literature.
At baseline and on each follow-up visit, patients
must be asked about any changes in visual acuity
and simple screening tests for acuity may be sufficient.
Should patients report changes in vision, an
ophthalmologist referral is then appropriate. Current
American Academy of Ophthalmology (AAO)
screening guidelines recommend that patients be prescribed
doses of hydroxychloroquine ≤6.5 mg/kg/
day or chloroquine ≤3mg/kg/day.102,103 Additionally,
the guidelines divide patients into those who are “low
risk” (receive lower dose for 60 years of age). Patients should
have a baseline ophthalmologic examination within
1 year of beginning the medication, which includes a

Hasil (Bahasa Indonesia) 1:

MONITORING THERAPYLaboratory monitoring should include a completeblood count performed monthly for 3 months to evaluatefor the presence of hemolytic (or, less commonly,aplastic) anemia. Thereafter, quarterly to semiannualcomplete blood counts should be obtained. A comprehensivemetabolic panel should be checked monthlyfor 3 months, then every 4–6 months thereafter, payingspecial attention to the liver enzymes, particularly inthose patients who are taking hepatotoxic medicationsand in those patients with porphyria. Quarterly tosemiannual chemistries should be followed while onmaintenance therapy.Proposed guidelines for monitoring for the developmentof ocular toxicity vary widely in the literature.At baseline and on each follow-up visit, patientsmust be asked about any changes in visual acuityand simple screening tests for acuity may be sufficient.Should patients report changes in vision, anophthalmologist referral is then appropriate. CurrentAmerican Academy of Ophthalmology (AAO)screening guidelines recommend that patients be prescribeddoses of hydroxychloroquine ≤6.5 mg/kg/day or chloroquine ≤3mg/kg/day.102,103 Additionally,the guidelines divide patients into those who are “lowrisk” (receive lower dose for <5 years) and “high risk”(receive higher doses, have other risk factors suchas high body fat level, concomitant kidney, liver, orretinal disease, or >60 years of age). Patients shouldhave a baseline ophthalmologic examination within1 year of beginning the medication, which includes a

Hasil (Bahasa Indonesia) 2:

PEMANTAUAN TERAPI
pemantauan laboratorium harus mencakup lengkap
hitung darah dilakukan setiap bulan selama 3 bulan untuk mengevaluasi
keberadaan hemolitik (atau, lebih jarang,
aplastik) anemia. Setelah itu, kuartalan untuk setengah tahunan
jumlah darah lengkap harus diperoleh. Sebuah komprehensif
panel metabolik harus diperiksa setiap bulan
selama 3 bulan, maka setiap 4-6 bulan setelahnya, membayar
perhatian khusus pada enzim hati, terutama pada
pasien yang mengambil obat hepatotoksik
dan pada pasien dengan porfiria. Triwulan ke
kimia setengah tahunan harus diikuti saat
terapi pemeliharaan.
pedoman Usulan untuk pemantauan untuk pengembangan
toksisitas okular bervariasi dalam literatur.
Pada awal dan pada setiap kunjungan tindak lanjut, pasien
harus ditanya tentang perubahan ketajaman visual
dan sederhana tes skrining untuk ketajaman mungkin sudah cukup.
Jika pasien melaporkan perubahan dalam visi, sebuah
rujukan dokter mata kemudian tepat. Saat
American Academy of Ophthalmology (AAO)
pedoman skrining merekomendasikan bahwa pasien harus diresepkan
dosis hydroxychloroquine ≤6.5 mg / kg /
hari atau klorokuin ≤3mg / kg / day.102,103 Selain itu,
pedoman membagi pasien menjadi orang-orang yang "rendah
risiko "( menerima dosis yang lebih rendah untuk <5 tahun) dan "berisiko tinggi"
(menerima dosis yang lebih tinggi, memiliki faktor risiko lain seperti
sebagai tingkat tinggi lemak tubuh, ginjal bersamaan, hati, atau
penyakit retina, atau> 60 tahun). Pasien harus
menjalani pemeriksaan oftalmologi dasar dalam
1 tahun mulai obat, yang mencakup